Significant Decline in Investments in Israeli Life Sciences Companies in 2025
A newly published report presents a complex picture of the Health-Tech industry in Israel. While 2024 was characterized by a certain recovery in investments, 2025 brings new and significant challenges for companies in the sector.
According to the data, there has been a sharp 40% decrease in the volume of investments in Israeli life sciences companies during the current year. This represents a notable shift in trends, as the industry had hoped to continue the growth recorded last year.
In addition to the overall decline in investment amounts, the report points to another trend: a decrease in the average deal size. This means that companies in the field are finding it more difficult to raise large sums as they did in the past, which affects their ability to expand and develop new technologies.
Despite the concerning investment data, the report notes that relative stability is being maintained in the export sector. This figure indicates that the products and services of Israeli life sciences companies remain in demand and relevant in international markets.
The industry is now examining how to cope with the new economic reality. Market experts are closely monitoring the data, aiming to understand whether this is a temporary crisis or a long-term change in the way investors choose to support innovation in the Israeli healthcare sector.